AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 20808013
Drug: Continuous infiltration
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infiltration of bupivacaine to the subcutaneous tissue and intra‐articular space for 48 hours, in addition to PCA
Trial: 20808013
Drug: Intra‐articular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra‐articular injection of local anaesthetic followed by continuous infiltration of bupivacaine to the subcutaneous tissue and intra‐articular space for 48 hours, in addition to PCA
Trial: 20808013
Drug: Patient‐controlled analgesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient‐controlled analgesia (PCA) with intravenous morphine for 48 hours
Trial: 15063406
Drug: Group 2
RxNorm normalized name: Chlamydophila psittaci biogroup 2 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 2 (no therapy)
Trial: 11140921
Drug: Fluvoxamine (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine (up to 300 mg daily)
Trial: 27100415
Drug: PUD with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PUD with proton-pump inhibitors (PPIs) use
Trial: 22007026
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (LDL-C target < 130 mg/dL)
Trial: 22007026
Drug: Multifactorial treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multifactorial treatment
Trial: 20868531
Drug: Multifactorial adherence-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multifactorial adherence-based intervention (motivational interviews, pill reminders, family support, blood pressure self-recording, simplification of dosing regimen)
Trial: 18604566
Drug: Multimodal group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal group therapy program (20 treatment days over 10 weeks)
Trial: 15796645
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment with contingency management (CM) for 12 weeks
Trial: 10522578
Drug: mepivacaine 1%
RxNorm normalized name: mepivacaine 1% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mepivacaine 1% with 1 ml saline
Trial: 10522578
Drug: mepivacaine 1%
RxNorm normalized name: mepivacaine 1% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mepivacaine 1% with 5 ml saline
Trial: 10522578
Drug: mepivacaine 1.5%
RxNorm normalized name: mepivacaine 1.5% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mepivacaine 1.5% with 10 ml saline
Trial: 7009594
Drug: Weekly coated‐charcoal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly coated‐charcoal hemoperfusion (CCHP)
Trial: 23429100
Drug: N-MUF (3000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-MUF (3000 ml)
Trial: 19075045
Drug: Posaconazole (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posaconazole (400 mg) with acidic beverage
Trial: 19075045
Drug: Posaconazole (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posaconazole (400 mg) with higher gastric pH
Trial: 19075045
Drug: Posaconazole (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posaconazole (400 mg) plus nutritional supplement (Boost)
Trial: 19075045
Drug: Posaconazole (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posaconazole (200 mg) plus nutritional supplement (Boost)
Trial: 19075045
Drug: Posaconazole (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posaconazole (400 mg) during high-fat meal
Trial: 17488963
Drug: Intensive anti-ischemic
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive anti-ischemic drug therapy
Trial: 23146135
Drug: Growth Hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth Hormone (GH) treatment for 6 months
Trial: 25470087
Drug: Aripiprazole long-acting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole long-acting injection (LAI)
Trial: 23872254
Drug: Red ginseng
RxNorm normalized name: Red ginseng
DrugBank: Ginseng (DB01404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red ginseng extract (RGE) 1500 mg orally three times a day for 7 days
Trial: 18759293
Drug: Ocrelizumab (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ocrelizumab (doses of 200 mg and higher) plus MTX
Trial: 18759293
Drug: Ocrelizumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ocrelizumab (10 mg and 50 mg)
Trial: 10757543
Drug: Diet rich
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet rich in alpha-linolenic acid (8.3 g/d)
Trial: 8922306
Drug: N-acetylcysteine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine supplementation (600 mg daily for 3-9 months)
Trial: 4002807
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg indapamide once daily
Trial: 29385054
Drug: High d‐allulose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High d‐allulose (7 g × 2 times/day)
Trial: 19713253
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (oral antivirals and analgesics)
Trial: 14650210
Drug: mexidol, intravenously
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mexidol, intravenously instilled in a daily dose of 2‐4 mg/kg over a period of 10 days in combination with a standard neurometabolic scheme
Trial: 4061344
Drug: No Se
RxNorm normalized name: ZINC OXIDE 11.12 g in 50 mL TOPICAL CREAM [UV defense me. No sebum sunscreen]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No Se supplements (control)
Trial: 31050933
Drug: Diode laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diode laser (DL) as an adjunct to Kirkland flap surgery
Trial: 29179625
Drug: Pediatric malaria
RxNorm normalized name: Plasmodium malariae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pediatric malaria vaccine trial (GSK/PATH‐MVI RTS,S)
Trial: 25243680
Drug: STOPP/START medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STOPP/START medication intervention
Trial: 26861468
Drug: Usual pharmaceutical
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Usual pharmaceutical care
Trial: 20108006
Drug: Lidocaine 20
RxNorm normalized name: lidocaine 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 20 mg
Trial: 22526437
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of lidocaine 20 mg and nitroglycerin 0.1 μg/kg
Trial: 17610056
Drug: Levosimendan (24‐h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosimendan (24‐h infusion of 0.1 mug/kg/min)
Trial: 8194616
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate (CC), 100 mg from days 2 to 6
Trial: 8194616
Drug: Natural cycle
RxNorm normalized name: Natural Cycles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural cycle (no treatment)
Trial: 2048868
Drug: Norfloxacin, 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norfloxacin, 400 mg orally every 12 hours
Trial: 27771572
Drug: Matched placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo capsule
Trial: 12087344
Drug: St John's
RxNorm normalized name: St john's wort
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: St John's wort (single dose 900 mg)
Trial: 12087344
Drug: St John's
RxNorm normalized name: St john's wort
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: St John's wort (long-term treatment 300 mg 3 times a day)
Trial: 2612091
Drug: Oral cyclosporin
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cyclosporin A (CyA)
Trial: 23352604
Drug: Bevacizumab plus
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab plus FOLFIRI (5-fluorouracil 400mg/m² on day 1 plus 2,400 mg/m² as a 46-h infusion, leucovorin 400mg/m² on day 1, and irinotecan 180 mg/m² on day 1)
Trial: 21205360
Drug: Milk supplementation
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk supplementation (1000 mg Ca/d)
Trial: 11403365
Drug: High serum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High serum cholesterol (> 6.8 mmol/l)
Trial: 11403365
Drug: High serum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High serum creatinine (> 155 micromol/l)
Trial: 29855972
Drug: LY2963016 insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY2963016 insulin glargine (LY IGlar)
Trial: 24043733
Drug: Daily manual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily manual lymphatic drainage and bandaging followed by compression garments
Trial: 11405809
Drug: Almotriptan malate,
RxNorm normalized name: Almotriptan Malate, 6.25 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almotriptan malate, 12.5 mg
Trial: 11405809
Drug: Sumatriptan succinate,
RxNorm normalized name: SUMAtriptan Succinate, 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sumatriptan succinate, 50 mg
Trial: 24479576
Drug: Narrative Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narrative Therapy (NT)
Trial: 23389497
Drug: 3 additional
RxNorm normalized name: chromous chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 additional doses of L-asparaginase (6000 IU/m2/dose) during consolidation treatment (3A arm)
Trial: 23389497
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment without additional doses of L-asparaginase (0A arm)
Trial: 19892856
Drug: Placebo (detuned
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (detuned ultrasound therapy and detuned short‐wave therapy)
Trial: 15328092
Drug: Amoxicillin-clavulanate 2,000/125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin-clavulanate 2,000/125 mg
Trial: 11446908
Drug: Amoxicillin-clavulanate 875/125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin-clavulanate 875/125 mg
Trial: 10780133
Drug: No supportive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No supportive agent
Trial: 3119288
Drug: Levonorgestrel and
RxNorm normalized name: levonorgestrel and estrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levonorgestrel and Ethinylestradiol in tablet form (150/30)
Trial: 3119288
Drug: Levonorgestrel and
RxNorm normalized name: levonorgestrel and estrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levonorgestrel and Ethinylestradiol in capsule form
Trial: 14982548
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment plus CM with an expected maximum of $240 of reinforcement
Trial: 11709606
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy including sulphasalazine (SSZ; 2000 mg/day), methotrexate (MTX; 7.5 mg/week), and prednisolone (initially 60 mg/day, tapered to 7.5 mg/day)
Trial: 3367455
Drug: Oral acyclovir,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral acyclovir, 400 mg five times daily
Trial: 22005905
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of 0.5% hyperbaric bupivacaine (Group I)
Trial: 12624696
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg dolasetron orally
Trial: 3550340
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy (bleomycin, Cytoxan, methotrexate, and 5-fluorouracil) in two cycles (one cycle if no tumor response) followed by standard treatment (combined irradiation and surgery or primary irradiation alone)
Trial: 3550340
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard treatment without prior chemotherapy)
Trial: 16942534
Drug: Vardenafil (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vardenafil (20 mg)
Trial: 8277478
Drug: Treatment failures
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment failures
Trial: 18854540
Drug: Episodic amiodarone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Episodic amiodarone treatment
Trial: 16227760
Drug: Irbesartan/HCTZ treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan/HCTZ treatment regimen
Trial: 2286465
Drug: Co-trimoxazole (1.92
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-trimoxazole (1.92 g)
Trial: 29412363
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered 1 hour prior to bleaching
Trial: 25091062
Drug: Antimicrobial susceptibility-guided
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimicrobial susceptibility-guided therapy
Trial: 12565715
Drug: Warfarin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (2 mg per day)
Trial: 16551898
Drug: Nalbuphine (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalbuphine (0.1 mg/kg)
Trial: 31353988
Drug: Rational-emotive behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rational-emotive behaviour therapy
Trial: 28329434
Drug: COPE treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COPE treatment (Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure)
Trial: 20601736
Drug: Caffeine (CAF;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (CAF; 3.7 mg/kg BM)
Trial: 20601736
Drug: Carbohydrate (CON;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate (CON; 1.8 g/kg BM)
Trial: 16637728
Drug: Adper Prompt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adper Prompt L‐pop
Trial: 14509861
Drug: Cognitive‐behavioural stress
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive‐behavioural stress management/expressive supportive therapy (CBSM+) intervention
Trial: 11002624
Drug: subsyde-CR (diclofenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subsyde-CR (diclofenac in controlled release formulation using DRCM technology)
Trial: 11002624
Drug: meloxicam (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: meloxicam (standard formulation)
Trial: 1430680
Drug: Recombinant tissue-type
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant tissue-type plasminogen activator (rt-PA) treatment
Trial: 26633836
Drug: Dabigatran 150
RxNorm normalized name: dabigatran 150 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dabigatran 150 mg bid for seven days
Trial: 18034990
Drug: Target-controlled infusion
RxNorm normalized name: Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor
DrugBank: Tagraxofusp (DB14731)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Target-controlled infusion of propofol for sedation
Trial: 16130506
Drug: Oral disodium
RxNorm normalized name: etidronate disodium Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral disodium pamidronate combined with calcium salts and vitamin D3 supplements
Trial: 12193919
Drug: Surgical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical therapy (dilatation and curettage)
Trial: 6344896
Drug: Conventional diuretics
RxNorm normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional diuretics
Trial: 20814410
Drug: DAG oil
RxNorm normalized name: Daglutril
DrugBank: Daglutril (DB05796)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAG oil (15% of total caloric intake, mean intake 33.0 ± 3.1 g/day)
Trial: 20814410
Drug: TAG oil
RxNorm normalized name: ProVent SKIN TAG OIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAG oil (15% of total caloric intake, mean intake 33.0 ± 3.1 g/day)
Trial: 11748390
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg spinal ropivacaine
Trial: 11748390
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg spinal ropivacaine
Trial: 11748390
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg spinal ropivacaine
Trial: 31549623
Drug: Test (generic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test (generic formulation)
Trial: 31549623
Drug: Reference (branded
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference (branded formulation)
Trial: 25422824
Drug: 6.6‐mm long
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6.6‐mm long implants
Trial: 30515480
Drug: 9.6‐mm or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9.6‐mm or longer implants (augmented group)
Trial: 20026256
Drug: Nanosomal Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nanosomal Tacrolimus (5 mg/kg in rats, 10 mg/kg in mice)
Trial: 1673645
Drug: Esmolol 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol 100 mg
Trial: 1673645
Drug: Esmolol 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol 200 mg
Trial: 7337792
Drug: Study treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study treatment assigned to private physicians (specific treatment details not available)
Trial: 28233012
Drug: Supervised structured
RxNorm normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised structured exercise programme (aerobic and resistance exercises performed bi-weekly, plus at least 30 min of brisk daily walks)
Trial: 23955552
Drug: Intermittent tri-weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent tri-weekly docetaxel (75 mg m(‐2) once tri-weekly) plus bicalutamide (50 mg once daily)
Trial: 19815876
Drug: Artesunate (AS)
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Artesunate (AS) at 2 mg/kg
Trial: 19815876
Drug: Artesunate (AS)
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Artesunate (AS) at 4 mg/kg
Trial: 28044135
Drug: ECVVH treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ECVVH treatment for 72 hours
Trial: 28044135
Drug: Standard therapies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapies without ECVVH
Trial: 18551200
Drug: Fluticasone 250
RxNorm normalized name: FLUTICASONE 250MCG/BLSTR PO INH ROTADISK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone 250 microg/salmeterol 50 microg plus montelukast 10 mg (F/S + M)
Trial: 7352522
Drug: Oxygen administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen administration
Trial: 8942325
Drug: Paracetamol 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol 1.5 g
Trial: 8942325
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of paracetamol 1.5 g and diclofenac 100 mg
Trial: 29444699
Drug: Intracervically administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracervically administered terlipressin
Trial: 27510521
Drug: Voriconazole 400
RxNorm normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Voriconazole 400 mg twice daily on the first day and 200 mg twice daily thereafter
Trial: 27510521
Drug: Posaconazole 400
RxNorm normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Posaconazole 400 mg twice daily
Trial: 15049152
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg lycopene (Tomatol) per day during 24 weeks
Trial: 9814452
Drug: Calcium carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium carbonate (CaCO3-1000 mg/day in two divided doses)
Trial: 21593118
Drug: 1 ×
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 × 750 mg dose of metyrapone
Trial: 19331224
Drug: 10,000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10,000 IU epoetin-alpha thrice weekly
Trial: 16504956
Drug: 15% sage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15% sage spray (140 microl sage extract per dose)
Trial: 10904284
Drug: Enalapril (35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (35 mg/day)
Trial: 10904284
Drug: Losartan (175
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan (175 mg/day)
Trial: 10904284
Drug: Enalapril +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril + Losartan (15 mg + 100 mg/day)
Trial: 9060552
Drug: prednimustine 200
RxNorm normalized name: prednimustine
DrugBank: Prednimustine (DB12832)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: prednimustine 200 mg/m2/d for 5 days per month for 18 months
Trial: 27959713
Drug: Low-dose rivaroxaban
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose rivaroxaban (15 mg once daily) plus a P2Y12 inhibitor for 12 months